180 related articles for article (PubMed ID: 21658043)
21. Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval.
Cid J; Ramiro L; Escoda L; Llorente A
Vox Sang; 2009 Jan; 96(1):29-33. PubMed ID: 19121195
[TBL] [Abstract][Full Text] [Related]
22. Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.
Infanti L; Stebler C; Job S; Ruesch M; Gratwohl A; Irsch J; Lin L; Buser A
Transfus Apher Sci; 2011 Oct; 45(2):175-81. PubMed ID: 21840762
[TBL] [Abstract][Full Text] [Related]
23. Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres.
van der Meer PF; Couture C; Hervig T; Kruit G; Devine DV; de Korte D; Kerkhoffs JL
Vox Sang; 2017 Jan; 112(1):9-17. PubMed ID: 28001293
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma.
Vassallo RR; Adamson JW; Gottschall JL; Snyder EL; Lee W; Houghton J; Elfath MD
Transfusion; 2010 Nov; 50(11):2376-85. PubMed ID: 20497516
[TBL] [Abstract][Full Text] [Related]
25. [The efficacy and safety of autologous cryopreserved platelet transfusion in management of thrombocytopenia after chemotherapy in hematological malignancy].
Liu GQ; Ding HF; Lu XJ; Xu M; Xing J; Zhao X; Han F; Shang YH
Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):188-91. PubMed ID: 22781890
[TBL] [Abstract][Full Text] [Related]
26. New Emerging Developments of Platelets in Transfusion Medicine.
Stolla M; Kapur R; Semple JW
Transfus Med Rev; 2020 Oct; 34(4):207-208. PubMed ID: 33129605
[No Abstract] [Full Text] [Related]
27. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
Snyder E; McCullough J; Slichter SJ; Strauss RG; Lopez-Plaza I; Lin JS; Corash L; Conlan MG;
Transfusion; 2005 Dec; 45(12):1864-75. PubMed ID: 16371039
[TBL] [Abstract][Full Text] [Related]
28. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.
Rebulla P; Vaglio S; Beccaria F; Bonfichi M; Carella A; Chiurazzi F; Coluzzi S; Cortelezzi A; Gandini G; Girelli G; Graf M; Isernia P; Marano G; Marconi M; Montemezzi R; Olivero B; Rinaldi M; Salvaneschi L; Scarpato N; Strada P; Milani S; Grazzini G
Transfusion; 2017 May; 57(5):1171-1183. PubMed ID: 28236335
[TBL] [Abstract][Full Text] [Related]
29. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
Picker SM; Steisel A; Gathof BS
Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of riboflavin and ultraviolet light treatment against Klebsiella pneumoniae in whole blood-derived platelets: A pilot study.
Alabdullatif M; Osman IE; Alrasheed M; Ramirez-Arcos S; Alyousef M; Althawadi S; Alhumiadan H
Transfusion; 2021 May; 61(5):1562-1569. PubMed ID: 33687079
[TBL] [Abstract][Full Text] [Related]
31. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients.
Slichter SJ
J Clin Apher; 2006 Apr; 21(1):78-84. PubMed ID: 16619231
[TBL] [Abstract][Full Text] [Related]
32. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
[TBL] [Abstract][Full Text] [Related]
33. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial.
Heddle NM; Cook RJ; Blajchman MA; Barty RL; Sigouin CS; Boye DM; Nelson EJ; Kelton JG
Transfusion; 2005 Jun; 45(6):896-903. PubMed ID: 15934987
[TBL] [Abstract][Full Text] [Related]
34. Platelet transfusion therapy.
Slichter SJ
Hematol Oncol Clin North Am; 1990 Feb; 4(1):291-311. PubMed ID: 2179213
[TBL] [Abstract][Full Text] [Related]
35. Improving the bacteriological safety of platelet transfusions.
Blajchman MA; Goldman M; Baeza F
Transfus Med Rev; 2004 Jan; 18(1):11-24. PubMed ID: 14689374
[TBL] [Abstract][Full Text] [Related]
36. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.
Simonsen AC; Johansson PI; Conlan MG; Jacquet M; Lin JS; Junge K; Lin L; Sørensen H; Borregaard N; Flament J
Transfusion; 2006 Mar; 46(3):424-33. PubMed ID: 16533286
[TBL] [Abstract][Full Text] [Related]
37. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia.
Johansson PI; Simonsen AC; Brown PN; Ostrowski SR; Deberdt L; Van Hoydonck P; Yonemura SS; Goodrich RP
Transfusion; 2013 Sep; 53(9):2043-52. PubMed ID: 23278371
[TBL] [Abstract][Full Text] [Related]
38. Storage age of transfused platelets and outcomes after cardiac surgery.
Welsby IJ; Lockhart E; Phillips-Bute B; Campbell ML; Mathew JP; Newman MF; Peterson E; Milano CA;
Transfusion; 2010 Nov; 50(11):2311-7. PubMed ID: 20573071
[TBL] [Abstract][Full Text] [Related]
39. Proteomic analysis of extracellular vesicles derived from platelet concentrates treated with Mirasol® identifies biomarkers of platelet storage lesion.
Hermida-Nogueira L; Barrachina MN; Izquierdo I; García-Vence M; Lacerenza S; Bravo S; Castrillo A; García Á
J Proteomics; 2020 Jan; 210():103529. PubMed ID: 31605789
[TBL] [Abstract][Full Text] [Related]
40. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants.
Asano H; Lee CY; Fox-Talbot K; Koh CM; Erdinc MM; Marschner S; Keil S; Goodrich RP; Baldwin WM
Transplantation; 2007 Nov; 84(9):1174-82. PubMed ID: 17998874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
